Fixed-dose combination
Lamivudine and Zidovudine is a fixed-dose combination of a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor and a hepatitis B virus nucleoside analog reverse transcriptase inhibitor. It is available as tablets for oral use. MedsAcross supplies Lamivudine and Zidovudine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. COMBIVIR, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection.
Source: US FDA prescribing information
COMBIVIR is an antiretroviral agent.
Source: US FDA prescribing information
• Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily. • Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily. • Because COMBIVIR is a fixed‑dose tablet and cannot be dose adjusted, COMBIVIR is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose‑limiting adverse reactions.
Source: US FDA prescribing information
COMBIVIR is contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine.
Source: US FDA prescribing information
Boxed warning: Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease. Prolonged use of zidovudine has been associated with symptomatic myopathy. • Hepatic decompensation, some fatal, has occurred in HIV‑1/HCV co‑infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin. Discontinue COMBIVIR as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. • Exacerbation of anemia has been reported in HIV‑1/HCV co‑infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised.
Source: US FDA prescribing information
The following adverse reactions are discussed in other sections of the labeling: • Hematologic toxicity, including neutropenia and anemia. • Symptomatic myopathy. • Lactic acidosis and severe hepatomegaly with steatosis. • Exacerbations of hepatitis B. • Hepatic decompensation in patients co-infected with HIV‑1 and hepatitis C. • Exacerbation of anemia in HIV‑1/HCV co-infected patients receiving ribavirin and zidovudine. • Pancreatitis. • Immune reconstitution syndrome. • Lipoatrophy. • Most commonly reported adverse reactions (incidence greater than or equal to 15%) in clinical trials of combination lamivudine and zidovudine were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough.
Source: US FDA prescribing information
• Agents antagonistic with zidovudine: Concomitant use should be avoided. • Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. • Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations, when possible, avoid chronic coadministration.
Source: US FDA prescribing information
Store between 2° and 30°C (36° and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Lamivudine and Zidovudine, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Lamivudine and Zidovudine 150 mg/300 mg tabletOralGeneric name | Lamivudine and Zidovudine | — | US FDA | Available on request |
| Combivir 150 mg/300 mg tabletOral | Lamivudine and Zidovudine | ViiV Healthcare | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Lamivudine and Zidovudine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Lamivudine and Zidovudine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lamivudine and Zidovudine, including Combivir.
Yes. The US FDA first approved Lamivudine and Zidovudine on 26 September 1997, according to Drugs@FDA.
Yes. Lamivudine and Zidovudine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Lamivudine and Zidovudine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lamivudine and Zidovudine is classified under ATC code J05AR01 (Lamivudine and Zidovudine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.